Drugs / OligoG CF-5/20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00970346 | Sep → Oct 2009 | cystic fibrosis | AlgiPharma AS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-01 | AlgiPharma AS | Results AlgiPharma Study Published on Potentiation of Colistin. algipharma.com ↗
Addition of alginate oligosaccharide (OligoG CF-5/20) significantly improved colistin diffusion by 3.7 times through mucin-rich AS medium (at 48 h; p < 0.05). |
| 2010-01-05 | AlgiPharma AS | Results AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases algipharma.com ↗
OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-01 | AlgiPharma AS | AlgiPharma Study Published on Potentiation of Colistin. algipharma.com ↗ |
| 2010-01-05 | AlgiPharma AS | AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases algipharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OligoG CF-5/20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00970346 ↗ |
| Modality | Oligonucleotide (other) | “G-block Oligosaccharide Derived From Alginate Polysaccharide” NCT00970346 ↗ |
| Route | Inhaled | “Inhaled OligoG CF-5/20 will be given to healthy volunteers” NCT00970346 ↗ |